RCC

Germany-based immatics biotechnologies has completed patient recruitment for its Phase III trial evaluating renal cell carcinoma (RCC) vaccine IMA901.

The study is expected to randomise approximately 345 patients with metastatic and/or locally advanced RCC across 10 countries in the US and Europe.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

immatics CMO Dr Carsten Reinhardt said the rate of patient recruitment signifies the level of interest in the novel cancer vaccine for the treatment of renal cell carcinoma.

"IMA901, which contains multiple highly relevant tumor peptides, has already indicated the potential to extend patient survival and we look forward to this being confirmed in this pivotal trial," Reinhardt said.

The Phase III IMPRINT trial will evaluate the overall survival benefit of IMA901 in combination with sunitinib, in comparison to sunitinib alone.

See Also:

Immune response to the peptides contained in IMA901, progression-free survival, safety and tolerability are the secondary endpoints.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Interim overall survival results of the study are expected in the first half of 2014.

Immatics CEO Paul Higham said IMA901 has been designed to redirect the immune system to make it recognise and control tumours.

"We believe that our vaccines could deliver a step-change in the treatment of cancer patients, allowing them to live longer with their cancer while maintaining their quality of life," Higham said.

The US Food and Drug Administration (FDA) has granted orphan drug status to IMA901 for the treatment of renal cell carcinoma in HLA-A*02 positive patients.

Image: Renal cell carcinoma. Photo: Courtesy of Ed Uthman.